Eli Lilly and Company (LLY)vsPetMed Express Inc (PETS)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
PETS
PetMed Express Inc
$2.24
-0.88%
HEALTHCARE · Cap: $48.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 34762% more annual revenue ($65.18B vs $186.96M). LLY leads profitability with a 31.7% profit margin vs -34.7%. LLY appears more attractively valued with a PEG of 1.29. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
PETS
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+83.0%
Fair Value
$17.51
Current Price
$2.24
$15.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Earnings expanding 266.7% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of -100.6% — below average capital efficiency
Revenue declined 21.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : PETS
The strongest argument for PETS centers on Price/Book, EPS Growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : PETS
The primary concerns for PETS are PEG Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while PETS is a turnaround play — different risk/reward profiles.
PETS carries more volatility with a beta of 0.78 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 43/100), backed by strong 31.7% margins and 42.6% revenue growth. PETS offers better value entry with a 83.0% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →PetMed Express Inc
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
PetMed Express, Inc., doing business as 1-800-PetMeds, is a pet pharmacy in the United States. The company is headquartered in Delray Beach, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?